Dashboard
1
Poor Management Efficiency with a low ROCE of 2.72%
- The company has been able to generate a Return on Capital Employed (avg) of 2.72% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of -1.22% and Operating profit at -22.96% over the last 5 years
4
The company has declared Positive results for the last 5 consecutive quarters
5
With ROE of 4.51%, it has a fair valuation with a 1.35 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 10,112 Million (Large Cap)
30.00
NA
0.84%
0.18
4.26%
1.15
Revenue and Profits:
Net Sales:
1,288 Million
(Quarterly Results - Sep 2025)
Net Profit:
76 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.33%
0%
8.33%
6 Months
1.77%
0%
1.77%
1 Year
-6.99%
0%
-6.99%
2 Years
-13.57%
0%
-13.57%
3 Years
-8.19%
0%
-8.19%
4 Years
-34.27%
0%
-34.27%
5 Years
-43.25%
0%
-43.25%
Yifan Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.22%
EBIT Growth (5y)
-22.96%
EBIT to Interest (avg)
1.55
Debt to EBITDA (avg)
2.27
Net Debt to Equity (avg)
0.15
Sales to Capital Employed (avg)
0.43
Tax Ratio
10.01%
Dividend Payout Ratio
63.03%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.72%
ROE (avg)
3.20%
Valuation key factors
Factor
Value
P/E Ratio
30
Industry P/E
Price to Book Value
1.35
EV to EBIT
36.09
EV to EBITDA
18.26
EV to Capital Employed
1.30
EV to Sales
2.61
PEG Ratio
0.20
Dividend Yield
0.82%
ROCE (Latest)
3.61%
ROE (Latest)
4.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
1,287.60
1,298.10
-0.81%
Operating Profit (PBDIT) excl Other Income
107.00
281.70
-62.02%
Interest
16.50
12.40
33.06%
Exceptional Items
0.20
-0.50
140.00%
Consolidate Net Profit
76.10
145.90
-47.84%
Operating Profit Margin (Excl OI)
83.10%
144.10%
-6.10%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -0.81% vs -0.92% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -47.84% vs 5.57% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5,131.40
4,042.80
26.93%
Operating Profit (PBDIT) excl Other Income
735.50
289.30
154.23%
Interest
78.90
86.50
-8.79%
Exceptional Items
-67.90
-857.80
92.08%
Consolidate Net Profit
323.60
-885.60
136.54%
Operating Profit Margin (Excl OI)
76.00%
2.30%
7.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 26.93% vs 5.83% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 136.54% vs -796.77% in Dec 2023
About Yifan Pharmaceutical Co., Ltd. 
Yifan Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






